Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03866967
Recruitment Status : Recruiting
First Posted : March 7, 2019
Last Update Posted : March 7, 2019
Sponsor:
Collaborator:
Akeso Tiancheng, Inc
Information provided by (Responsible Party):
Akeso

Brief Summary:
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy (of which one of them must be platinum-based chemotherapy).

Condition or disease Intervention/treatment Phase
Nasopharyngeal Carcinoma Biological: AK105 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 153 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-arm, Open-label, Multicenter, Phase II Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy
Estimated Study Start Date : March 1, 2019
Estimated Primary Completion Date : June 15, 2020
Estimated Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AK105
Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
Biological: AK105
intravenous (IV) infusion




Primary Outcome Measures :
  1. Objective response rate (ORR) in the full analysis set (FAS) population [ Time Frame: up to 2 years ]
    ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

  2. ORR in the PD-L1 positive population [ Time Frame: up to 2 years ]
    ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: up to 2 years ]
    PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) or death from any cause (whichever occurs first).

  2. Disease control rate (DCR) [ Time Frame: up to 2 years ]
    DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1.

  3. Duration of response (DoR) [ Time Frame: up to 2 years ]
    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

  4. Overall survival (OS) [ Time Frame: up to 2 years ]
    OS is defined as the time from the date of randomization to death from any cause.

  5. Incidence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: From the time of informed consent signed through 90 days after last dose of AK105 ]
    An adverse event (AE) is any untoward medical occurrence or the deterioration of existing medical event in a clinical study subject administered an investigational drug, which does not necessarily have an unequivocal causal relationship with the investigational product.

  6. Observed concentrations of AK105 [ Time Frame: From first dose of AK105 through 90 days after last dose of AK105 ]
    The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.

  7. Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK105 through 90 days after last dose of AK105 ]
    The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent form voluntarily.
  • Age over 18 years old (inclusive) and not more than 70 years old (inclusive), when signing the ICF.
  • Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
  • Expected life expectance ≥ 3 months.
  • Histologically confirmed diagnosis of nonkeratinizing differentiated or undifferentiated NPC.
  • Not suitable for radical local therapy.
  • Stage IVb metastatic NPC patients who have failed the first-line platinum-based chemotherapy and the second-line chemotherapy.
  • At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously treated with local therapies such as radiotherapy can be considered a target lesion if there is objective evidence of progression in the lesion.
  • Subjects must provide an available tumor tissue sample taken within 3 years prior to enrollment.
  • Adequate organ function.
  • Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception.
  • Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and for 120 days after the last dose of investigational product.

Exclusion Criteria:

  • Receipt of last radiotherapy or any anti-tumor treatment [chemotherapy, targeted therapy, immunotherapy, Chinese herbal drugs with antitumor indications, or immunomodulators or tumor embolization] within 4 weeks prior to the first dose of study treatment. Nitrosourea or mitomycin C treatment within 6 weeks prior to the first dose of AK105.
  • Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as ICOS or agonists (e.g. CD40, CD137, GITR and OX40 etc).
  • Other invasive malignancies within 5 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
  • Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, with the exceptions of the following: vitiligo, alopecia, Grave disease, psoriasis or eczema not requiring systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of hormone replacement therapy and type I diabetes only requiring steady doses of insulin replacement therapy, or completely relieved childhood asthma that requires no intervention in adulthood, or primary diseases that will not relapse unless triggered by external factors.
  • Active or previously documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis or chronic diarrhea).
  • Subjects who require systemic corticosteroids (a dose equivalent to >10 mg/day prednisone) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
  • Known history of testing positive for human immunodeficiency virus (HIV).
  • Known history of primary immunodeficiency virus infection.
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • History of gastrointestinal perforation and/ or fistula within 6 months prior to enrollment.
  • Necrotic lesion(s) found by examinations within 4 weeks prior to enrollment, which, in the investigator's opinion, is at risk of massive bleeding.
  • Known history of interstitial lung disease.
  • Known history of active tuberculosis (TB).
  • Serious infections within 4 weeks prior to the first dose of study drug, including but not limited to complications requiring hospitalization, sepsis or severe pneumonia.
  • An active infection requiring systemic therapy.
  • Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA <500 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative.
  • Major surgery (as defined by the investigator) within 30 days prior to the first dose of study drug.
  • Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease, or active brain metastasis.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.
  • Receipt of live or attenuated vaccination within 30 days prior to the first dose of study treatment, or plan to receive live or attenuated vaccine during the study.
  • Known history of server hypersensitivity to other monoclonal antibodies.
  • Known severe allergic reactions to paclitaxel, carboplatin, or their preventive medications.
  • Known allergic reactions to any ingredients of AK105.
  • Pregnant or lactating women.
  • Any conditions that, in the investigator's opinion, may put subjects treated with the study drug at risks, or interfere with the evaluation of study drug or subject safety, or the interpretation of study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866967


Contacts
Layout table for location contacts
Contact: Xiaoping Jin +86-0760-89873999 clinicaltrials@akesobio.com

Locations
Layout table for location information
China, Beijing
Beijing Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Principal Investigator: Yan Sun, MD         
China, Shanghai
FuDan University Shanghai Cancer Center Recruiting
Shanghai, Shanghai, China, 200032
Contact: , MD         
Principal Investigator: Chaosu Hu, MD         
Sponsors and Collaborators
Akeso
Akeso Tiancheng, Inc
Investigators
Layout table for investigator information
Principal Investigator: Chaosu Hu, MD Fudan University

Layout table for additonal information
Responsible Party: Akeso
ClinicalTrials.gov Identifier: NCT03866967     History of Changes
Other Study ID Numbers: AK105-202
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Akeso:
immunotherapy
Anti-PD-1 antibody
Nasopharyngeal Carcinoma
immuno-oncology

Additional relevant MeSH terms:
Layout table for MeSH terms
Nasopharyngeal Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Carcinoma
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases